GGrantIndex
← Leaderboards

Michael D Prados

University Of California San Francisco

$7,364,703
Attributed
$12,884,858
Total exposure
14
Grants
0
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.6M · FY200513
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13

Funding mix

By agency

NIH$17,549,229 · 15

By mechanism

U01$16,767,042 · 5
M01$782,187 · 10

Top collaborators

Most similar at University Of California San Francisco

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research

Research focus

Clinical ResearchHuman SubjectGliomaHuman Therapy EvaluationNeoplasm /Cancer ChemotherapyBrain NeoplasmsClinical TrialsClinical Trial Phase INeoplasm /Cancer Relapse /RecurrenceCooperative StudyDrug Screening /EvaluationAntineoplasticsStatistics /BiometryTemozolomideCombination ChemotherapyPatient Oriented ResearchComputer Data AnalysisCarmustineHealth Science Research SupportDosageCollaborationsInstitutionCollectionLeadership

Grant awards (56)

Adult Brain Tumor Consortium (ABTC)$1,698,364
U01 · FY2013 · CA
Adult Brain Tumor Consortium (ABTC)$1,818,177
U01 · FY2012 · CA
Adult Brain Tumor Consortium (ABTC)$1,905,232
U01 · FY2011 · CA
Adult Brain Tumor Consortium (ABTC)$1,989,811
U01 · FY2010 · CA
Adult Brain Tumor Consortium (ABTC)$2,000,000
U01 · FY2009 · CA
Adult Brain Tumor Consortium (ABTC)$885,989
U01 · FY2009 · CA
Adult Brain Tumor Consortium (ABTC)$742,737
U01 · FY2009 · CA
NABTC Central Operation Grant (UCSF Project Leader)$653,728
U01 · FY2008 · CA · contact PI
NABTC Central Operation Grant (UCSF Project Leader)$650,493
U01 · FY2007 · CA · contact PI
NABTC Central Operation Grant (UCSF Project Leader)$388,972
U01 · FY2005 · CA
NABTC 01-08: PHASE II TRIAL OF STI571 (NSC 716051) IN RECURRENT MENINGIOMA$9,821
M01 · FY2005 · RR
A PHASE I STUDY OF OSI-774 AND TEMOZOLOMIDE FOR THE TREATMENT OF GLIOMAS$4,209
M01 · FY2005 · RR
A PHASE II TRIAL OF POLY ICLC IN PATIENTS WITH RECURRENT ANAPLASTIC GLIOMA$1,403
M01 · FY2005 · RR
ZD1839 FOR MALIGNANT ASTROCYTOMA OR GLIOBLASTOMA AND MENINGIOMA$931
M01 · FY2005 · RR
NABTC - Foreign Accrual$0
U01 · FY2005 · CA
NABTC Central Operation Grant (UCSF Project Leader)$685,516
U01 · FY2004 · CA
A Phase I Study of OSI-774 and Temozolomide for the Treatment of Gliomas$49,589
M01 · FY2004 · RR
Phase I/II trial of ST1571 in children with newly diagnosed brainstem gliomas$10,711
M01 · FY2004 · RR
OSI-774 in Recurrent Malignant Gliomas &Malignant Gliomas Post Radiation Tx$6,085
M01 · FY2004 · RR
Phase I/II Trial of R115777 in Patients With Recurrent Malignant Glioma$4,867
M01 · FY2004 · RR
NABTC 01-08: Phase II Trial of STI571 (NSC 716051) in Recurrent Meningioma$3,651
M01 · FY2004 · RR
A Phase II Trial of Poly ICLC in Patients with Recurrent Anaplastic Glioma$3,042
M01 · FY2004 · RR
ZD1839 and Temozolomide for Gliomas$609
M01 · FY2004 · RR
ZD1839 for Malignant Astrocytoma or Glioblastoma and Meningioma$609
M01 · FY2004 · RR
NABTC CENTRAL OPERATION GRANT (UCSF PROJECT LEADER)$611,069
U01 · FY2003 · CA
NABTC MEMBER INSTITUTION GRANT (UCSF PROJECT LEADER)$166,663
U01 · FY2003 · CA
PEDIATRIC BRAIN TUMOR CLINICAL TRIAL CONSORTIUM$117,775
U01 · FY2003 · CA
NABTC CENTRAL OPERATION GRANT (UCSF PROJECT LEADER)$569,659
U01 · FY2002 · CA
NABTC MEMBER INSTITUTION GRANT (UCSF PROJECT LEADER)$155,388
U01 · FY2002 · CA
PEDIATRIC BRAIN TUMOR CLINICAL TRIAL CONSORTIUM$115,088
U01 · FY2002 · CA
NABTC 9702--PHASE I TRIAL OF PRESURGICAL 06-BENZYLGUANINE$68,666
M01 · FY2002 · RR
Adenovirus mediated wild type p53 gene therapy for gliom$68,666
M01 · FY2002 · RR
Trial of irinotecan (CPT-11) in recurrent malignant glio$68,666
M01 · FY2002 · RR
PHASE II TRIAL THYMIDINE &CARBOPLATIN FOR RECURRENT MALIGNANT GLIOMA$68,666
M01 · FY2002 · RR
PHASE II TRIAL OF TEMOZOLOMIDE &BCNU FOR MALIGNANT GLIOMAS$68,666
M01 · FY2002 · RR
NABTC CENTRAL OPERATION GRANT (UCSF PROJECT LEADER)$557,806
U01 · FY2001 · CA
NABTC MEMBER INSTITUTION GRANT (UCSF PROJECT LEADER)$154,638
U01 · FY2001 · CA
PEDIATRIC BRAIN TUMOR CLINICAL TRIAL CONSORTIUM$113,812
U01 · FY2001 · CA
NABTC 9702--PHASE I TRIAL OF PRESURGICAL 06-BENZYLGUANINE$68,666
M01 · FY2001 · RR
Adenovirus mediated wild type p53 gene therapy for gliom$68,666
M01 · FY2001 · RR
Trial of irinotecan (CPT-11) in recurrent malignant glio$68,666
M01 · FY2001 · RR
PHASE II TRIAL THYMIDINE &CARBOPLATIN FOR RECURRENT MALIGNANT GLIOMA$68,666
M01 · FY2001 · RR
PHASE II TRIAL OF TEMOZOLOMIDE &BCNU FOR MALIGNANT GLIOMAS$68,666
M01 · FY2001 · RR
PHASE II TRIAL THYMIDINE &CARBOPLATIN FOR RECURRENT MALIGNANT GLIOMA$0
M01 · FY2001 · RR
NABTC 9702--PHASE I TRIAL OF PRESURGICAL 06-BENZYLGUANINE$0
M01 · FY2001 · RR
Adenovirus mediated wild type p53 gene therapy for gliom$0
M01 · FY2001 · RR
PHASE II TRIAL OF TEMOZOLOMIDE &BCNU FOR MALIGNANT GLIOMAS$0
M01 · FY2001 · RR
Trial of irinotecan (CPT-11) in recurrent malignant glio$0
M01 · FY2001 · RR
NABTC CENTRAL OPERATION GRANT (UCSF PROJECT LEADER)$547,128
U01 · FY2000 · CA
NABTC MEMBER INSTITUTION GRANT (UCSF PROJECT LEADER)$127,082
U01 · FY2000 · CA
PEDIATRIC BRAIN TUMOR CLINICAL TRIAL CONSORTIUM$111,915
U01 · FY2000 · CA
PHASE II TRIAL OF TEMOZOLOMIDE &BCNU FOR MALIGNANT GLIOMAS$0
M01 · FY2000 · RR
Adenovirus mediated wild type p53 gene therapy for gliom$0
M01 · FY2000 · RR
Trial of irinotecan (CPT-11) in recurrent malignant glio$0
M01 · FY2000 · RR
PHASE II TRIAL THYMIDINE &CARBOPLATIN FOR RECURRENT MALIGNANT GLIOMA$0
M01 · FY2000 · RR
NABTC 9702--PHASE I TRIAL OF PRESURGICAL 06-BENZYLGUANINE$0
M01 · FY2000 · RR